Exozymes Inc.
EXOZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002010788
In the last 90 days, Exozymes Inc. insiders filed 1 open-market purchase and 0 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.05M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Exozymes Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $6.41K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$6.41K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Exozymes Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Nawaz Fouad | Vice President- Finance | 9,488 | Sep 17, 2026 | 2 |
| Heltzen Michael | Chief Executive Officer | 13,853 | Sep 2, 2026 | 1 |
| Perriman Damien Alan | Chief Commercial Officer | 28,499 | Aug 25, 2026 | 3 |
| Korman Tyler Paz | Chief Scientific Officer | 762,837 | Aug 25, 2026 | 3 |
| Opgenorth Paul Hideo | Vice President, Development | 645,149 | Apr 8, 2026 | 1 |
| MDB Capital Holdings, LLC | 10% Owner | 3,931,133 | Nov 18, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 (view filing)7:33 PM ET | Aug 25-26 | 8 daysLate | Heltzen MichaelChief Executive Officer | PPurchase | +855 | $7.49 | +$6.41K | +6.5%14.0K after | 5 lots |
| Apr 10, 2026 (view filing) | Apr 8-9 | 2 days | Korman Tyler PazChief Scientific Officer | SSale | −1.50K | $10.29 | −$15.4K | −0.2%729.1K after | 2 lots |
| Jul 2, 2025 (view filing) | Jul 2 | Same day | Heltzen MichaelChief Executive Officer | PPurchase | +1.04K | $10.22 | +$10.6K | +10.8%10.6K after | |
| Jan 21, 2025 (view filing) | Jan 16-17 | 5 days | Heltzen MichaelChief Executive Officer | PPurchase | +1.89K | $10.78 | +$20.3K | +95.2%3.87K after | 2 lots |
| Nov 19, 2024 (view filing) | Nov 15 | 4 days | Heltzen MichaelChief Executive Officer | PPurchase | +1.98K | $11.10 | +$22.0K | New position1.98K after |